RE:TSX Uplisting ExpectationsNice to see you have joined the realist community. Maybe we can actually have some meaningful discussion instead of pointless pumping.
Uplist likely won't do anything for price but HOPEFULLY will create liquidity if the market makers are able do their job. It is also something that needed to be done many many months ago, so a tick off management's todo checklist.
The presentation won't have an impact or if it does, it'll be short lived especially if we aren't on the TSX by then. It could have a bigger impact if patient 3 is off insulin WITHOUT the need of a portal vein top up. An update on patients 4,5, 6 & 7 would certainly not hurt.
They could get some price uptick if they release any pre-clinical data they have using Evotecs cells and also any positive conformal coating pre-clinical data in primates if possible. No one cares about rats.
I'd also be questioning management about how much they are paying LifeSci and what value LifeSci are providing for said payment. As far as I can see, they have promoted a few basic news articles that are mostly paid adverts. Other than that, I don't see anything. If someone knows otherwise, please let me know. We need to hold management accountable for spending big $ on PR with 0 results. I'd be expecting to see some big stories on major news outlets or get rid of them. Spill still hasn't figured out that you don't need an expensive PR firm if you don't have any news to release. If you're paying them, start pumping out as much news as you can as I'm guessing they are paid on a monthly basis.
MoneyMouth wrote: Personally, I am not expecting a big jump up in share price when we uplist to the TSX. It'll probably be a pretty uneventful and anti-climactic day honestly. However, what I do expect from the uplisting is some sustained growth. My hope is that this uplisting will bring stability so that when the share price moves up 10 or 20 points, that those prices hold and real support is formed. Gains right now hold no water and are quickly erased. I hope that being on the better exchange with more accessibility will mean that when value is added to the company, value is also added to the share price as well. This has not been the case.
So what'll be the next catalyst and when we get to see if this uplisting changes anything? I'm really not sure. I don't think June 6th's presentation will be all that impactful. Its likely to contain the same information we diligent investors already know. i.e. 3 insulin independent patients, reduction in hypoglycemic events, reduction in hba1c yadda yadda yadda. After that, the next real news will be in the form of advancing the thyroid program to the clinic, and that won't be happening until the end of 2022 or more likely beginning of 2023. Maybe one other new piece of news would be finding out patient 7 has been implanted with the new 10 plug pouch?